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Objectives. Analyze the results in terms of local control, survival and toxicity.
Materials and Methods. We performed a retrospective observational study which analyzed data from 31 patients diagnosed with
thymoma and thymic carcinoma between February 1998 and June 2009, according to the classiﬁcation of Masaoka the 38.7%,
29%, 19%, 12.9% were classiﬁed in stage II, III, IVA and IVB respectively, according to the WHO classiﬁcation 3.2%, 21.4%, 21.4%,
3.6%, 10.7% and 39.3% were A, AB, B1, B2, B3 and C respectively.
Results. Of the 31 patients analyzed, 35.5% were male and 64.5% female, with a mean age of 53.5 years (27–74 years). The 35.5%
of patients were diagnosed with thymic carcinoma (operated 45.5%) and 64.5% of patients with thymoma (operated 75%). At
diagnosis, 29% of patients had a paraneoplasic Syndrome, the most frequent myasthenia gravis (66.7%). Unoperated patients
received adjuvant radioterpia with a mean dose of 5940 cGy, with local control of 73.3%. Postoperative patients received a mean
dose of 5040 cGy, with 85% local control. Patients receiving QT were 48.4%, of whom 53.3% were Thymoma and 46.7% thymic
carcinoma, of which 46.7% developed distant metastases With 145 months (12 years) follow-up 55.5% of the patients are alive,
with amedian overall survival of 71months, and a local control in 80%of patients. Of all patients, 87%developed during treatment
acute toxicity, but only 3.22% of patients had G3 pneumonitis and pericarditis.
Conclusions. In our study we obtained a good local control of patients treated with radiotherapy, being higher if associated with
surgery. The toxicity associated with the treatment is generally low grade. Although in our series is not reached statistical
signiﬁcance we have obtained good results in local control.
http://dx.doi.org/10.1016/j.rpor.2013.03.776
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Objectives. In order to implement the No Action Level with Correction Veriﬁcation setup protocol (NAL+COVER) for systematic
error correction in patient positioning, we detail a Monte Carlo simulation developed in Matlab to determine the random error
distribution from a set of off-line measurements of the misalignment of treatment ﬁelds and patient anatomy. This distribution
is needed for the protocol conﬁguration before its clinical implementation. We continue with a detailed description of a practical
way to coordinate treatment sessions with the protocol steps and the deﬁnition of a decision diagram to organize the protocol
execution by the radiotherapy technicians.
Methods. An ofﬂine analysiswas performed at theNALprotocol conﬁguration step on the positioningmisalignments of 36 patients
with radiation therapy treatment in the pelvic region using the Varis Review application of Varian Medical Systems. By means
of a Monte Carlo simulation we achieved the random error distribution for our population.
Results. The width of the random error distribution is 2 mm in all directions and from this value we designed a decision diagram
to implement the protocol and we deﬁned a method to coordinate treatment sessions with the protocol steps. Once the algorithm
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